A Narrative Review on the Pathophysiology of Preeclampsia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Preeclampsia (PE) is a multifactorial pregnancy disorder characterized by hypertension and proteinuria, posing significant risks to both maternal and fetal health. Despite extensive research, its complex pathophysiology remains incompletely understood. This narrative review aims to elucidate the intricate mechanisms contributing to PE, focusing on abnormal placentation, maternal systemic response, oxidative stress, inflammation, and genetic and epigenetic factors. This review synthesizes findings from recent studies, clinical trials, and meta-analyses, highlighting key molecular and cellular pathways involved in PE. The review integrates data on oxidative stress biomarkers, angiogenic factors, immune interactions, and mitochondrial dysfunction. PE is initiated by poor placentation due to inadequate trophoblast invasion and improper spiral artery remodeling, leading to placental hypoxia. This triggers the release of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), causing widespread endothelial dysfunction and systemic inflammation. Oxidative stress, mitochondrial abnormalities, and immune dysregulation further exacerbate the condition. Genetic and epigenetic modifications, including polymorphisms in the Fms-like tyrosine kinase 1 (FLT1) gene and altered microRNA (miRNA) expression, play critical roles. Emerging therapeutic strategies targeting oxidative stress, inflammation, angiogenesis, and specific molecular pathways like the heme oxygenase-1/carbon monoxide (HO-1/CO) and cystathionine gamma-lyase/hydrogen sulfide (CSE/H2S) pathways show promise in mitigating preeclampsia’s effects. PE is a complex disorder with multifactorial origins involving abnormal placentation, endothelial dysfunction, systemic inflammation, and oxidative stress. Despite advances in understanding its pathophysiology, effective prevention and treatment strategies remain limited. Continued research is essential to develop targeted therapies that can improve outcomes for both mothers and their babies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565
Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release
Zorov, D. B., Juhaszova, M., & Sollott, S. J. (2014) · Physiological Reviews · doi:10.1152/physrev.00026.2013 · Cited by 5,383
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720 · cited 1×
“…disruption of balance between pro-angiogenic factors (vascular endothelial growth factor (VEGF), placental growth factor (PlGF)), and anti-angiogenic factors (sFlt-1, sEng), impairing blood vessel formation and function, which results in endothelial dysfunction and reduced placental perfusion [23].”
BackgroundGestational Hypertension and Preeclampsia
(2020) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003891 · Cited by 2,949 · cited 1×
“It is primarily identified by the onset of hypertension after the 20th week of gestation and is frequently accompanied by dysfunction in multiple organs, including the kidneys, liver, blood, brain, and placenta [3,4].”
BackgroundLatest Advances in Understanding Preeclampsia
Redman, C. W., & Sargent, I. L. (2005) · Science · doi:10.1126/science.1111726 · Cited by 2,607
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Rana (2019) · doi:10.1161/circresaha.118.313276 · Cited by 2,095 · cited 1×
“Finally, the placental aging hypothesis attributes PE to placental aging, characterized by telomere shortening, cellular senescence, oxidative stress, and impaired placental function, increasing PE risk [16,18,26].”
BackgroundBisphenol A and Reproductive Health: Update of Experimental and Human Evidence, 2007–2013
Peretz, J., Vrooman, L., Ricke, W. A., Hunt, P. A., Ehrlich, S., Hauser, R., Padmanabhan, V., Taylor, H. S., Swan, S. H., VandeVoort, C. A., et al. (2014) · Environmental Health Perspectives · doi:10.1289/ehp.1307728 · Cited by 555
Long-term neuropsychiatric morbidity in children exposed prenatally to preeclampsia
Nahum Sacks, K., Friger, M., Shoham-Vardi, I., Sergienko, R., Spiegel, E., Landau, D., & Sheiner, E. (2019) · Early Human Development · doi:10.1016/j.earlhumdev.2019.01.016 · Cited by 59
Metadata
- Authors
- Torres-Torres, J., Espino-y-Sosa, S., Martinez-Portilla, R., Borboa-Olivares, H., Estrada-Gutierrez, G., Acevedo-Gallegos, S., Ruiz-Ramirez, E., Velasco-Espin, M., Cerda-Flores, P., Ramirez-Gonzalez, A., & Rojas-Zepeda, L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-07-10
- Volume
- 25
- Issue
- 14
- Pages
- 7569
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4400585356
- Cited by
- 184
- References
- 9
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.